Ministère de l'Emploi et de la Solidarité sociale
Consolidated Statutes and Regulations Consolidated Statutes Consolidated Regulations Annual Statutes and Regulations Annual Statutes Annual Regulations Additional information Québec Official Publisher What’s new? Information note Policy of the Minister of Justice Laws: Amendments Laws: Provisions not in force Laws: Provisions brought into force Annual Statutes: PDF versions since 1996 Regulations: Amendments Annual Regulations: PDF versions since 1996 Court Decisions

P-12, r. 6 - Regulation respecting the medications that a podiatrist who obtained a permit to practise before 1976 may administer or prescribe

Table of contents
Occurrences0
Current Version
Full text
Updated to 1 September 2012
This document has official status.
chapter P-12, r. 6
Regulation respecting the medications that a podiatrist may use in the practice of his profession or administer or prescribe to his patients
Podiatry Act
(chapter P-12, s. 12).
1. A podiatrist entered on the roll of the Ordre des podiatres du Québec may use in the practice of his profession or administer or prescribe to his patients the medications listed in Schedule I or in Schedule II, subject to the conditions prescribed in this Regulation.
A podiatrist who administers or prescribes to patients the medications listed in Schedule II that are not medications listed in Schedule I must hold a certificate issued by the Ordre des podiatres du Québec acknowledging that the podiatrist received university training in podiatric medicine in the last 5 years, comprising a minimum of 1145 hours apportioned as follows:
(1)  540 hours in anatomy-physiology;
(2)  90 hours in biochemistry;
(3)  105 hours in microbiology;
(4)  275 hours in general pathologies;
(5)  90 hours in basic pharmacology; and
(6)  45 hours in clinical pharmacology.
A podiatrist whose training referred to in subparagraphs 1 to 6 of the second paragraph was received more than 5 years previously must successfully complete the continuing education activities determined by the Ordre des podiatres du Québec pursuant to paragraph o of section 94 of the Professional Code (chapter C-26) and hold a certificate issued by the Order acknowledging that the activities were successfully completed, before the medications listed in Schedule II that are not medications listed in Schedule I may be administered to patients.
O.C. 1057-91, s. 1; O.C. 142-2003, s. 1.
2. (Revoked).
O.C. 1057-91, s. 2; O.C. 142-2003, s. 2.
3. (Omitted).
O.C. 1057-91, s. 3.
NOTE : Medications without specification are intended for topical application.

________________________________________________________________

Substances Specification
________________________________________________________________

Acetaminophen Pharmaceutical forms intended
for oral and rectal
administration

Acetic, glacial acid

Acetylsalicylic, Pharmaceutical forms intended
for oral administration

Aluminium and its salts

Almond, sweet oil

Amino acids

Amcinonide Quantity limited for 30 days

Anthralin (dithranol)

Silver nitrate

Silver sulfadiazine

Colloidal oatmeal

Bacitracin and its salts

Beclomethasone and its salts

Benzalkonium

Benzocaine

Betamethasone benzoate

Betamethasone Quantity limited for 30 days
dipropionate

Betamethasone valerate

Bupivacaine and Pharmaceutical forms intended
its salts for administration by injection
for local use only

Calcipotriol

Calcium acetate

Camphor

Cantharin

Capsaicin

Cetrimide

Cetirizine Pharmaceutical form intended
hydrochloride for oral administration

Chlorhexidine and its salts

Chlorphenesin

Chlorprocaine Pharmaceutical form intended
hydrochloride for administration by injection
for local use only

Ciclopirox olamine

Cinchocaine

Clioquinol
(iodochlorhydroxyquin)

Clobetasol Quantity limited for 30 days
proprionate

Clobetasone butyrate

Clotrimazole

Collagenase

Dakin’s solution

Desonide

Desoximetasone Quantity limited for 30 days

Deoxyribonuclease

Dichloracetic acid

Diflucortolone Quantity limited for 30 days
valerate

Diphenhydramine Pharmaceutical forms intended
for oral and topical
administration

Econazole nitrate

Epinephrine Pharmaceutical forms for the
(adrenaline) emergency treatment of
anaphylactic reactions in
the form of self-injector or
vial

Pharmaceutical form associated
with local anaesthetics

Erythromycin

Ethyl chloride

Fibrinolysin

Flumetasone pivalate

Fluocinolone Quantity limited for 30 days
acetonide

Fluocinode Quantity limited for 30 days

Formalin

Framycetin sulfate

Fusidic acid

Gentamicin sulfate

Gentian, violet

Mineral and vegetal tar

Gramicidin

Halcinodide Quantity limited for 30 days

Hexachlorophene

Mineral oil

Hydrocortisone and its salts

Hydroxyzine Pharmaceutical form intended
hydrochloride for oral administration

Povidone iodine

Iodine tincture

Isopropyl myristate

Ketoconazole

Lactic acid

Lanolin

Lidocaine and Pharmaceutical forms intended
its salts for topical application and
administration by injection
for local use only

Loratadine Pharmaceutical form intended
for oral administration

Lorazepam Pharmaceutical form intended
for oral and sublingual
administration in anticipation
of surgical procedures,
containing 0.5 mg or 1 mg
of Lorazepam per tablet

Quantity limited to 4 tablets

Mafenide and its salts

Menthol

Mepivacaine Pharmaceutical form intended
for administration by injection
for local use only

Methylpolysiloxanes

Methylprednisolone acetate

Miconazole nitrate

Mometasone furorate

Mupirocin

Neomycin sulfate

Nystatin

Oxiconazole

Phenol

Podophyllin

Polymyxin B sulfate

Pramoxine

Prilocaine Pharmaceutical forms intended
for topical application and
administration by injection
for local use only

Procaine Pharmaceutical form intended
for administration by injection
for local use only

Resorcinol and its salts

Diethylamine salicylate

Magnesium salicylate

Methyl salicylate

Triethanolamine salicylate

Salicylic acid

Synthetic sebum

Silicone

Sodium thiosulfate

Sulphur, colloidal,
precipitate or sublimate

Tazarotene

Terbinafine

Tetracaine and Pharmaceutical forms intended
its salts for topical application and
administration by injection
for local use only

Tioconazole

Tolnaftate

Triamcinolone Quantity limited for 30 days
acetonide

Trichloroacetic acid

Urea Pharmaceutical form intended
for topical application, with
a concentration of 30% or less

White petroleum jelly

Zinc oxide
O.C. 1057-91, Sch. I; O.C. 142-2003, s. 3; O.C. 522-2005, s. 1.
NOTE : Medications without specification are intended for topical application.

________________________________________________________________

Substances Specification
________________________________________________________________

Acetaminophen Pharmaceutical form intended
for oral and rectal administration

Acetaminophen and Pharmaceutical form intended
codeine for oral administration
(in combination) containing 30 mg or less of
codeine per tablet

Acetic, Quantity limited to 24 tablets/
glacial acid 72 hours

Acetylsalicyclic Pharmaceutical form intended
acid for oral administration

Aluminium and its salts

Almond, sweet oil

Amcinonide Quantity limited for 30 days

Amino acids

Anthralin (dithranol)

Silver nitrate

Silver sulfadiazine

Colloidal oatmeal

Bacitracin and its salts

Beclomethasone and its salts

Benzalkonium

Benzocaine

Betamethasone Pharmaceutical forms
acetate and intended for administration by
phosphate intramuscular or intradermal
injection

Betamethasone benzoate

Betamethasone Quantity limited for 30 days
dipropionate

Betamethasone valerate

Bleomycin sulfate Pharmaceutical form injectable in
the plantar lesion without
exceeding 0.8 units up to a maximum
of 5 units per treatment

Bupivacaine and Pharmaceutical form intended for
its salts administration by injection for
local use only

Calcipotriol

Calcium acetate

Camphor

Cantharin

Capsaicin

Celecoxib Pharmaceutical form intended for
oral administration

Quantity limited for 30 days

Cetirizine Pharmaceutical form intended for
hydrochloride oral administration

Cetrimid

Chlorhexidine and its salts

Chlorphenesin

Chlorprocaine Pharmaceutical form intended for
hydrochloride administration by injection for
local use only

Ciclopirox olamine

Cinchocaine

Clioquinor
(iodochlorhydroxyquin)

Clobetasol Quantity limited for 30 days
proprionate

Clobetasone butyrate

Clotrimazole

Collagenase

Dakin’s solution

Desonide

Desoximetasone Quantity limited for 30 days

Deoxyribonuclease

Dichloracetic acid

Diclofenac, Pharmaceutical form intended
potassic and sodic for oral administration

Quantity limited for 30 days

Diflucortolone Quantity limited for 30 days
valerate

Dyphenhydramine Pharmaceutical forms intended
for oral administration and
administration by intramuscular,
subcutaneous or intradermal
injection

Econazole nitrate

Epinephrine Pharmaceutical forms for the
(adrenaline) emergency treatment of
anaphylactic reactions in the
form of auto-injector or vial

Pharmaceutical form associated
with local anaesthetics

Erythromycin

Ethyl chloride

Fibrinolysin

Flumetasone pivalate

Fluocinolone Quantity limited for 30 days
acetonide

Fluocinode Quantity limited for 30 days

5-fluorouracil 0.1% pharmaceutical form intended
for topical application in the
case of plantar warts resistant to
first-line treatments

Formaline

Framycetin sulfate

Fusidic acid

Gentamicin sulfate

Gentian, violet

Mineral and vegetal tar

Gramicidin

Halcinodide Quantity limited for 30 days

Hexachlorophene

Mineral oil

Hydrocortisone and its salts

Hydroxyzine Pharmaceutical form intended for
hydrochloride oral administration

Ibuprofen Pharmaceutical form intended for
oral administration

Quantity limited for 30 days

Povidone iodine

Iodine tincture

Isopropyl myristate

Ketoconazole

Lactic acid

Lanolin

Lidocaine and Pharmaceutical forms intended for
its salts topical application and
administration by injection for
local use only

Loratadine Pharmaceutical form intended for
oral administration

Lorazepam Pharmaceutical form intended for
oral and sublingual administration
in anticipation of surgical
procedures, containing 0.5 mg or
1 mg of Lorazepam per tablet

Quantity limited to 4 tablets

Mafenide and its salts

Menthol

Mepivacaine Pharmaceutical form intended for
administration by injection
for local use only

Methylpolysiloxanes

Methylprednisolone Pharmaceutical forms intended for
acetate topical application and
administration by injection for
local use only
Miconazole nitrate

Mometasone furorate

Mupirocin

Naproxen Pharmaceutical form intended for
oral administration

Quantity limited for 30 days

Neomycin sulfate

Nystatin

Oxiconazole

Phenol

Podophyllin

Polymyxin B sulfate

Pramoxine

Prilocaine Pharmaceutical forms intended for
topical application and
administration by injection for
local use only

Procaine Pharmaceutical form intended for
administration by injection for
local use only

Resorcinol and its salts

Rofecoxib Pharmaceutical form intended for
oral administration
Quantity limited for 30 days

Diethylamine salicylate

Magnesium salicylate

Methyl salicylate

Triethanolamine salicylate

Salicylic acid

Synthetic sebum

Silicone

Sodium thiosulfate

Sulphur, colloidal,
precipitate or sublimate

Tazarotene

Terbinafine

Tetracaine and Pharmaceutical forms intended for
its salts topical application and
administration by injection for
local use only
Tioconazole

Tolnaftate

Triamcinolone Quantity limited for 30 days
acetonide

Triamcinolone Pharmaceutical forms intended for
hexacetonide administration by intramuscular or
intradermal injection
Quantity limited for 30 days

Trichloroacetic acid

Urea Pharmaceutical form intended for
topical application, with a
concentration of 30% or less

White petroleum jelly

Zinc oxide
O.C. 142-2003, s. 3; O.C. 522-2005, s. 2.
REFERENCES
O.C. 1057-91, 1991 G.O. 2, 3231
O.C. 142-2003, 2003 G.O. 2, 1013
O.C. 522-2005, 2005 G.O. 2, 1872
© Gouvernement du Québec